Erratum to "Comparison of continual insulin or secretagogue treatment in type 2 diabetic patients with alternate insulin-secretagogue administration" [Diabetes Res. Clin. Pract. 84 (2) (2009) 158-162] (DOI:10.1016/j.diabres.2009.01.020);Comparison of continual insulin or secretagogue treatment in type 2 diabetic patients with alternate insulin-secretagogue administration

Diabetes Research and Clinical Practice

Volumn 84, Issue 2, 2009, Pages 158-162

  Li, Hong ^a   Li, Wenjun ^a   Gu, Yao ^a   Han, Yuqi ^a   Wang, Jiying ^a   Xu, Bei ^a   Li, Fang ^a   Yu, Yongchun ^a   Wu, Guoting ^a  

^a NONE   (China)

Author keywords

Insulin; Sulfonylureas; Type 2 diabetes

Indexed keywords

C PEPTIDE; GLICLAZIDE; GLIPIZIDE; GLIQUIDONE; HEMOGLOBIN A1C; INSULIN; METFORMIN; REPAGLINIDE; ROSIGLITAZONE;

ADULT; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC PATIENT; DRUG EFFICACY; FEMALE; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TEST MEAL; THERAPY; WEIGHT GAIN;

EID: 63649162821     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2009.06.010     Document Type: Erratum

References (19)

1. Alvarsson M., Sundkvist G., Lager I., Henricsson M., Berntorp K., Fernqvist-Forbes E., et al. Beneficial effects of insulin versus sulphonylurea on insulin secretion and metabolic control in recently diagnosed type 2 diabetic patients. Diabetes Care 26 (2003) 2231-2237
2. Bizzarri C., Lucidi V., Ciampalini P., Bella S., Russo B., and Cappa M. Clinical effects of early treatment with insulin glargine in patients with cystic fibrosis and impaired glucose tolerance. J. Endocrinol. Invest. 29 (2006) RC1-4
3. Dailey III G.E. Early insulin: an important therapeutic strategy. Diabetes Care 28 (2005) 220-221
4. Glaser B., and Cerasi E. Early intensive insulin treatment for induction of long-term glycaemic control in type 2 diabetes. Diabetes Obes. Metab. (1999) 67-74
5. Kahn S.E. Beta cell failure: causes and consequences. Int. J. Clin. Pract. Suppl. 123 (2001) 13-18
6. Gangji A.S., Cukierman T., Gerstein H.C., Goldsmith C.H., and Clase C.M. A systematic review and meta-analysis of hypoglycemia and cardiovascular events: a comparison of glyburide with other secretagogues and with insulin. Diabetes Care 30 (2007) 389-394
7. Lee T.M., Lin M.S., Tsai C.H., Huang C.L., and Chang N.C. Effects of sulfonylureas on left ventricular mass in type 2 diabetic patients. Am. J. Physiol. Heart Circ. Physiol. 292 (2007) H608-613
8. Holman R.R. Long-term efficacy of sulfonylureas: a United Kingdom prospective diabetes study perspective. Metabolism 55 (2006) S2-5
9. Bermúdez-Pirela V.J., Cano C., Medina M.T., Souki A., Lemus M.A., Leal E.M., et al. Metformin plus low-dose glimeperide significantly improves Homeostasis Model Assessment for insulin resistance (HOMA(IR)) and beta-cell function (HOMA(beta-cell)) without hyperinsulinemia in patients with type 2 diabetes mellitus. Am. J. Ther. 14 (2007) 194-202
10. Papanas N., Tziakas D., Chalikias G., Floros D., Trypsianis G., Papadopoulou E., et al. Gliclazide treatment lowers serum ICAM-1 levels in poorly controlled type 2 diabetic patients. Diabetes Metab. 32 (2006) 344-349
11. Yoshihara T., Kumashiro N., Kanazawa Y., Mita T., Sakurai Y., Kawai J., et al. Therapeutic efficacy of mitiglinide combined with once daily insulin glargine after switching from multiple daily insulin regimen of aspart insulin and glargine in patients with type 2 diabetes mellitus. Endocr. J. 53 (2006) 67-72
12. Mari A., Gastaldelli A., Foley J.E., Pratley R.E., and Ferrannini E. Beta-cell function in mild type 2 diabetic patients: effects of 6-month glucose lowering with nateglinide. Diabetes Care 28 (2005) 1132-1138
13. Iwase M., Nakamura U., Uchizono Y., Nohara S., Sasaki N., Sonoki K., et al. A non-sulfonylurea rapid insulin secretagogue, increases pancreatic islet blood flow in rats. Eur. J. Pharmacol. 22 (2005) 243-250
14. National islet β-cell study group of China. Plasma glucose, insulin and C-peptide changes in normal subjects during steamed-bread meal test. Zhonghua Yi Xue Za Zhi 62 (1982) 643--647
15. Spellman C.W. Islet cell dysfunction in progression to diabetes mellitus. J. Am. Osteopath. Assoc. 107 (2007) S1-5
16. Wajchenberg B.L. Beta-cell failure in diabetes and preservation by clinical treatment. Endocr. Rev. 28 (2007) 187-218
17. Alexandra E.B., Juliette J., Susan B.-W., Robert R., Robert A.R., and Butler P.C. β-Cell deficit and increased β-cell apoptosis in humans with type 2 diabetes. Diabetes 52 (2003) 102-110
18. Kärvestedt L., Andersson G., Efendic S., and Grill V. A rapid increase in beta-cell function by multiple insulin injections in type 2 diabetic patients is not further enhanced by prolonging treatment. J. Intern. Med. 251 (2002) 307-316
19. Aldhahi W., Armstrong J., Bouche C., Carr R.D., Moses A., and Goldfine A.B. Beta-cell insulin secretory response to oral hypoglycemic agents is blunted in humans in vivo during moderate hypoglycemia. J. Clin. Endocrinol. Metab. 89 (2004) 4553-4557